YES: Tasigna (nilotinib) - was initially used as sencond line treatment for CML for patients resistant or intolerant to imatinib. Now it is indicated for first line treatment in CML in chronic phase. Its not a trial but treatment for cml. And yes you are right, we only have 24 month data to date as first line treatment.
Answered 6/10/2014
5.9k views
A doctor has provided 1 answer
A doctor has provided 1 answer
9 doctors weighed in across 3 answers
3 doctors weighed in across 2 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question